An open-label, multi-center, prospective clinical trial was performed among 78 PCR-confirmed COVID-19 patients admitted to the ICU with severe or life-threatening symptoms. Convalescent plasma therapy combined with standard treatment (n = 28) was compared to standard treatment alone (n = 50), stratified by disease severity.